EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin

Jan Thomann, Karolina E Kolaczynska, Oliver V Stoeckmann, Deborah Rudin, Patrick Vizeli, Marius C Hoener, Christopher R Pryce, Franz X Vollenweider, Matthias E Liechti, Urs Duthaler

Frontiers in Pharmacology · 29.04.2024 · 15

DOI: 10.3389/fphar.2024.1391689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2024. Verfasst von Jan Thomann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds Zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vivo , psilocybin is rapidly dephosphorylated to psilocin which induces psychedelic effects by interacting with the 5-HT 2A receptor. Psilocin primarily undergoes glucuronidation or conversion to 4-hydroxyindole-3-acetic acid (4-HIAA). Herein, we investigated psilocybin’s metabolic pathways in vitro and in vivo , conducting a thorough analysis of the enzymes involved. Metabolism studies were performed using human liver microsomes (HLM), cytochrome P450 (CYP) enzymes, monoamine oxidase (MAO), and UDP-glucuronosyltransferase (UGT). In vivo , metabolism was examined using male C57BL/6J mice and human plasma samples. Approximately 29% of psilocin was metabolized by HLM, while recombinant CYP2D6 and CYP3A4 enzymes metabolized nearly 100% and 40% of psilocin, respectively. Notably, 4-HIAA and 4-hydroxytryptophol (4-HTP) were detected with HLM but not with recombinant CYPs. MAO-A transformed psilocin into minimal amounts of 4-HIAA and 4-HTP. 4-HTP was only present in vitro . Neither 4-HIAA nor 4-HTP showed relevant interactions at assessed 5-HT receptors. In contrast to in vivo data, UGT1A10 did not extensively metabolize psilocin in vitro . Furthermore, two putative metabolites were observed. N -methyl-4-hydroxytryptamine (norpsilocin) was identified in vitro (CYP2D6) and in mice, while an oxidized metabolite was detected in vitro (CYP2D6) and in humans. However, the CYP2D6 genotype did not influence psilocin plasma concentrations in the investigated study population. In conclusion, MAO-A, CYP2D6, and CYP3A4 are involved in psilocin’s metabolism. The discovery of putative norpsilocin in mice and oxidized psilocin in humans further unravels psilocin’s metabolism. Despite limitations in replicating phase II metabolism in vitro , these findings hold significance for studying drug-drug interactions and advancing research on psilocybin as a therapeutic agent.

Schlagwörter

Stichwörter der Autor:innen

5-HT receptorcytochrome P450 (CYP)liver microsomesmetabolismpharmacokineticspsilocybinpsychedelicsrecombinant enzymes

Autor:innen und Institutionen

  • Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
  • Neuroscience Research, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Department of Psychiatry, Psychotherapy and Psychosomatics, Preclinical Laboratory for Translational Research Into Affective Disorders, University of Zurich, Zurich, Switzerland.
  • Department of Psychiatry, Psychotherapy and Psychosomatics, Neurophenomenology and Consciousness, University of Zurich, Zurich, Switzerland.
  • Institute of Forensic Medicine, Department of Biomedical Engineering, University of Basel, Basel, Switzerland.

Förderung

  • Schweizerischer Nationalfonds Zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Thomann, J., Kolaczynska, K. E., Stoeckmann, O. V., Rudin, D., Vizeli, P., Hoener, M. C., Pryce, C. R., Vollenweider, F. X., Liechti, M. E., & Duthaler, U. (2024). In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1391689

Vancouver

Thomann J, Kolaczynska KE, Stoeckmann OV, Rudin D, Vizeli P, Hoener MC, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1391689

BibTeX
@article{Thomann2024,
  author = {Thomann, Jan and Kolaczynska, Karolina E and Stoeckmann, Oliver V and Rudin, Deborah and Vizeli, Patrick and Hoener, Marius C and Pryce, Christopher R and Vollenweider, Franz X and Liechti, Matthias E and Duthaler, Urs},
  title = {In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1391689}
}
Kostenlos starten →